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Abstract
Background: Susac syndrome (retinocochleocerebral vasculopathy) is an autoimmune endotheliopathy affecting
the precapillary arterioles of the brain, retina, and inner ear. It presents with encephalopathy, branch retinal artery
occlusions, and hearing loss. The condition is often under recognized because the clinical symptoms may present
at different times and physicians may be unfamiliar with the syndrome. Peripheral findings would be helpful in
early diagnosis. There are numerous treatment regimens proposed with varying effectiveness.
Case presentation: We report the case of a 22-year-old Caucasian man in whom there were prominent skin
findings, including livedo reticularis and a micropapular eruption which responded promptly to treatment
suggesting that skin involvement may facilitate earlier diagnosis. Rituximab has occasionally been used in more
refractory disease. We observed a prompt response to the combination of intravenous immunoglobulin,
corticosteroids, and rituximab instituted immediately after diagnosis.
Conclusions: A careful search for dermatological manifestations may help with earlier diagnosis. Skin findings may
be another marker of endothelial cell involvement. Early use of rituximab as part of the therapeutic regimen may
be warranted.
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Background
Susac syndrome (SuS) (retinocochleocerebral vasculopathy)
is an autoimmune endotheliopathy affecting the precapil-
lary arterioles of the brain, retina, and inner ear. The major
manifestations are the clinical triad of encephalopathy,
branch retinal artery occlusions (BRAOs), and hearing loss.
First described by neurologist JO Susac in 1979, more than
300 cases have been described to date [1, 2]. The condition
is often under recognized because clinical symptoms asso-
ciated with the triad may present independently at different
times and physicians may be unfamiliar with the syndrome.
Of note, case reports have described associated dermato-
logical manifestations that might help facilitate earlier
diagnosis [3]. Different therapeutic regimens have
been described with varying results. More than 10
regimens are listed as options by experts at Cleveland
Clinic [4]. While all include intravenous immunoglobulin
(IVIG) and steroid therapy, other medications suggested
are mycophenolate mofetil, cyclophosphamide, and
azathioprine as well as plasmapheresis. The use of rituxi-
mab has occasionally been reported in more refractory
disease unresponsive to initial therapy [5, 6].
We report a case of SuS, in which there was a prompt
response to the combination of IVIG, corticosteroids,
and rituximab for the cerebral, ophthalmologic, and oto-
laryngological manifestations. We further document
prominent skin findings including livedo reticularis and
a micropapular eruption that responded promptly to
treatment, confirming that skin involvement may* Correspondence: elie.x.gertner@healthpartners.com1Section of Rheumatology, Regions Hospital, 640 Jackson Street, St. Paul, MN
55101, USA
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occasionally be a manifestation of the syndrome and
may help with early diagnosis.
Case presentation
A 22-year-old Caucasian man with a past medical his-
tory of depression was admitted to our hospital with a
2-week history of headache, progressive confusion,
and behavioral changes, including hallucination. One
week prior to his symptoms, our patient developed a
livedo-like reticular skin lesion involving both upper
extremities and a diffuse pink rash on his chest. A
review of his other medical systems was unremarkable. In
particular, he had no visual or hearing difficulties and
no neck stiffness. There was no infectious exposure and
no seizure activity. His medications included sertraline
and buspirone.
Pertinent findings on examination included a confused
young man who was only oriented to person. A derma-
tological examination revealed skin lesions compatible
with livedo reticularis on his upper extremities (Fig. 1)
and a diffuse micropapular faint pink eruption with a
“sandpaper” quality on his chest and abdomen. There was
no prior history of rash. There were no active or effused
joints. A neurological examination revealed mild dysmetria
with finger-nose-finger testing and limb ataxia. His Mini
Mental Status Examination (MMSE) score was 16/30.
Results of a complete blood count, basic metabolic
panel, and urine analysis were unremarkable. His results
were negative for ANCA. Tests for anti-dsDNA, Sm, Ro,
La, centromere, Scl-70, and RNP antibodies were nega-
tive, as were all tests for antiphospholipid antibodies and
myositis-specific antibodies.
Brain MRI with intravenous contrast revealed restricted
diffusion involving the splenium of the corpus callosum
(red arrowhead) and punctate lesions within the subcor-
tical white matter (black arrows) (Fig. 2). There was
enhancement of the leptomeninges as well as the subcor-
tical lesions (not shown). Neither an MRA of his head/
neck nor a conventional cerebral angiogram showed any
vasculopathy. A lumbar puncture revealed a cerebrospinal
fluid (CSF) protein concentration of 278 mg/dl with a
normal glucose concentration and cell count. All CSF
infectious studies were negative. An EEG showed diffuse
slowing consistent with diffuse encephalopathy.
Fundoscopic examination demonstrated fluffy white
patches along the inferotemporal arcade (Fig. 3). Fluor-
escein angiography confirmed 14 BRAOs and arterial
wall hyperfluorescence with leakage of dye.
An audiogram was initially normal and speech recog-
nition thresholds were normal bilaterally.
The livedo lesion was biopsied and examination of the
specimen revealed congestion of dermal vessels without
inflammation of the vessel walls. The micropapular
eruption revealed superficial perivascular lymphocytic
infiltration.
Based on the cerebral and eye findings, a diagnosis of
likely SuS was made. Our patient was started on
Fig. 1 Livedo reticularis-like skin manifestation occurring on both
arms, but nowhere else, 1 week before presentation and resolving
with treatment
Fig. 2 Axial brain magnetic resonance imaging sequences with
diffusion-weighted imaging (DWI) revealed multifocal subacute
punctate supratentorial white matter lesions (black arrows) with the
most prominent lesion affecting the posterior corpus callosum (red
arrowhead). The study also showed T2/fluid attenuated inversion
recovery (FLAIR) hyperintensities involving the deep gray nuclei as
well as leptomeningeal enhancement (not shown)
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methylprednisolone 1 g daily × 5 days given intraven-
ously. On day 1 of the diagnosis he also received IVIG
500 mg/kg. On day 2 he received 1000 mg of rituximab,
followed by IVIG 500 mg/kg on day 3 and day 4. He was
started on Pneumocystis jirovecii pneumonia prophylaxis
and a proton-pump inhibitor. On day 6, his steroid was
changed to prednisone 1 mg/kg/day given orally. Within a
week his confusion and neurological symptoms improved
and by the second week his repeat MMSE score was
30/30. A Repeatable Battery for Neuropsychological Status
(RBANS) showed cognitive performances ranging from
average to superior. The livedo lesions and the micro-
papular rash resolved within 10 days of treatment.
After 1 week he developed sudden hearing loss. An
audiogram showed severe left-sided sensorineural hearing
loss. Speech reception thresholds were obtained at 15
decibels hearing level (dBHL) on his right and 50 dBHL
on his left. Word recognition was 100 % at 55 dBHL on
his right and 8 % at 90 dBHL on his left. An intratympanic
steroid injection was performed in his left middle ear and
repeated three times over a 2-week period with moderate
improvement in his word recognition score.
Repeat fluorescein angiography after 2 weeks and on
subsequent testing showed stable filling defects but no
new retinal vascular lesions. His left ear word recognition
improved over the next month to 52 %.
His treatment regimen over the next 6 months included
a gradual taper and discontinuation of steroids, addition
of azathioprine as a long-term immunosuppressive agent
(mycophenolate mofetil was not tolerated), low-dose
aspirin, and IVIG every 2 weeks. Repeat brain MRI showed
no progression of his disease and improvement compared
with previous studies.
After the first month of treatment, he was able to resume
all his daily activities without difficulty or recurrence.
Discussion
SuS (retinocochleocerebral vasculopathy) is an auto-
immune endotheliopathy associated with the clinical
triad of CNS dysfunction, BRAOs, and sensorineural
hearing loss [2, 7]. Most cases present in patients
between 16 and 40 years of age. While CNS symptoms
are the most common manifestation, the characteristic
clinical triad occurs at disease onset in only a minority
of patients. Because of this, the diagnosis may be de-
layed; in fact, diagnosing SuS solely on the basis of the
presence of the complete triad may not be appropriate.
CNS symptoms include headaches, often resembling
migraine-like headaches, confusion, cognitive impair-
ment, ataxia, and vertigo. Ophthalmological involvement
includes many types of disturbances including blurring
and flashing. Hearing loss is the major otological mani-
festation. Other manifestations include myalgia and arth-
ralgia. A few patients have been described to have skin
lesions [2, 3].
Involvement of the corpus callosum with evidence of
“snowball” lesions is a characteristic MRI finding [8].
Supratentorial white matter and gray matter lesions as
well as infratentorial lesions and leptomeningeal enhance-
ment are all found. Fundoscopic examination followed by
fluorescein angiography reveals BRAO and arterial wall
hyperfluorescence. Audiometry reveals sensorineural hear-
ing loss, which is often bilateral. In patients with suspected
SuS, MRI of the brain, fluorescein angiography, and audi-
ometry must be routinely performed even in the absence
of clinical manifestations. No specific serological anti-
body studies have been identified with this syndrome.
Cerebrospinal fluid analysis often reveals an elevation of
protein, sometimes in combination with a mild lymphocytic
pleocytosis. Cerebral angiography is usually normal. A brain
biopsy can show microinfarcts and a microangiopathic
process with arteriolar wall thickening and lymphocytic
infiltration [9].
The differential diagnosis of SuS includes various neuro-
logical, psychiatric, and ophthalmologic disorders includ-
ing multiple sclerosis, vasculitis, infection, neuromyelitis
optica, and acute disseminated encephalomyelitis [2, 10].
While the etiology remains unclear, it has been suggested
that the microvascular occlusions are mediated by an
autoimmune response causing microvascular injury.
Anti-endothelial cell antibodies have been detected in
some patients. The finding of antiphospholipid antibodies
in one case of SuS raised the possibility of an autoimmune
endotheliopathy/coagulopathy [1, 11].
Fig. 3 Fundoscopic examination revealed fluffy white patches along
the inferotemporal arcade
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Controlled trials of treatment are not available. Expert
recommendations suggest treatment regimens similar to
those successful with juvenile dermatomyositis, which
has some characteristics in common with SuS [12].
More than 10 therapeutic regimens are listed as options
by the experts (Robert Rennebohm, MD) at Cleveland
Clinic [4]. All include IVIG and steroid therapy. Other
medications include mycophenolate mofetil, cyclophos-
phamide, and azathioprine. Cyclophosphamide for the
acute phase of treatment followed by maintenance
therapy with methotrexate or long-term therapy with
mycophenolate mofetil and methotrexate have been
reported to be successful in case reports [13, 14]. The use
of rituximab has occasionally been reported in more
refractory disease [5, 6]. The ideal regimen has yet to be
determined.
The choice of therapies and their mechanism of action
are based on the similarities between SuS and juvenile
dermatomyositis. The histopathology and electron micro-
scopic findings in the microvasculature of the brain and
muscle of patients with SuS are reminiscent of the micro-
vascular abnormalities seen in the muscle and skin of chil-
dren with dermatomyositis, including endothelial cell
swelling, endothelial cell degeneration and necrosis, capil-
lary network destruction, and perivascular lymphocytic in-
filtration. Because both may represent microvascular
endotheliopathies, immunosuppressive medication used
in juvenile dermatomyositis may be helpful in SuS [12].
Our patient had remarkable improvement of his CNS
function (MMSE score 30/30) and no further eye lesions
2 weeks after the prompt initiation of high-dose cortico-
steroids, IVIG, and rituximab. One week into the course
he developed hearing loss, which was treated with the
addition of intratympanic steroids with moderate im-
provement. The use of intratympanic steroids has been
reported on occasion [15, 16]. Although it appears to
have been moderately successful in our patient, it re-
mains unclear whether the improvement was related to
this local treatment, systemic therapy, or both. Our ex-
perience with this patient demonstrates that the majority
of patients need immediate, aggressive immunotherapy
even before confirmation of the clinical triad of symp-
toms and that they can respond well, particularly if
symptoms have not been present for a long time. Ste-
roids, IVIG, and rituximab may be a useful induction
therapy. Steroids have been tapered successfully in our
patient and he is being maintained on IVIG infusions
and azathioprine.
In this case, livedo reticularis was a prominent mani-
festation prior to presentation and resolved within 1–2
weeks of treatment. Similarly, the micropapular rash
with the nonspecific findings of perivascular lymphocytic
infiltration resolved with the treatment rapidly. Dorr et al.
[2] found 13 reported cases of dermatological findings
(mainly livedo reticularis) in SuS. Livedo reticularis results
from an impairment of blood flow in the dermal arteries,
which is due to many causes including spasm, inflamma-
tion, and vascular obstruction. Its appearance at the onset
of the disease and resolution with treatment of the
underlying disease suggests that the underlying etiological
processes responsible for the other manifestations contri-
buted to the livedo reticularis lesions. Turc et al. [3]
reported a case of SuS preceded by a 2-week history of
livedo racemosa. Skin biopsies revealed several occluded
dermal arterioles, endothelial cell swelling, and a mild
perivascular lymphocytic infiltrate. The pathology in our
case was somewhat similar although the dermal arterioles
were not as involved. His rashes responded quickly to
therapy. Subtle skin lesions may thus be an early and
visible manifestation of the syndrome, which otherwise
centers around the brain, retina, and inner ear.
Conclusions
SuS can be a challenging disorder to recognize initially.
The characteristic clinical features with appropriate testing
can help make the diagnosis. This case report supports an
aggressive therapeutic approach involving the combination
of steroids, IVIG, and rituximab administered early in the
disease process and highlights the associated dermato-
logical manifestations, which may further serve as a marker
of endothelial cell involvement.
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